NCT07900984Not yet recruiting
A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 63 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- Oct 2026
- Primary completion date
- Feb 2027
- Lead sponsor
- Varian, a Siemens Healthineers Company
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07900984
What you commit to
- Study type: Observational
- Planned participants: 63
- From Oct 2026 to the primary completion date, Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Undergone radioembolization or other radiotherapy to the liver.
Who the study is looking for
- Undergone at least one MWA treatment in the liver using dual channel ablation on the Intelliblate MWA system.
- At least 30 days of follow-up post treatment for safety and 8 weeks (-4 weeks, +8 weeks) follow-up for imaging to assess complete ablation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.